COMPENDIUM ON FUNCTIONAL MEDICINE - Flipbook - Page 642
immune processes early, Array 22 creates opportunities for more
targeted, comprehensive interventions that address not only the
bacteria themselves but also the immune activation they trigger.
This approach aligns with emerging research showing that SIBO
and IBS are not merely functional disorders but complex conditions
involving immune dysregulation, barrier dysfunction, and
microbiome disturbances. For patients suffering from these
challenging conditions, comprehensive assessment that includes
immune factors offers new hope for more effective, personalized
treatment strategies.
References
[1] Pimentel M, et al. Small intestinal bacterial overgrowth: a
framework for understanding IBS. Gastroenterology.
2020;158(7):2003-2015.
[2] Quigley EM. Small intestinal bacterial overgrowth: what it is and
what it is not. Curr Opin Gastroenterol. 2014;30(2):141-146.
[3] Vojdani A. The role of pathogenic bacteria in the development
of autoimmunity. Autoimmune Dis. 2014;2014:301958.
[4] Ghoshal UC, Shukla R, Ghoshal U. Small intestinal bacterial
overgrowth and irritable bowel syndrome: a bridge between
functional organic dichotomy. Gut Liver. 2017;11(2):196-208.
[5] Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial
overgrowth: a comprehensive review. Gastroenterol Hepatol (N
Y). 2007;3(2):112-122.
[6] Mantis NJ, Rol N, Corthésy B. Secretory IgA's complex roles in
immunity and mucosal homeostasis in the gut. Mucosal Immunol.
2011;4(6):603-611.
[7] Fagarasan S, Kawamoto S, Kanagawa O, Suzuki K. Adaptive
immune regulation in the gut: T cell-dependent and T
cell-independent IgA synthesis. Annu Rev Immunol.
2010;28:243-273.
642
